Actuate Therapeutics, Inc.
ACTU- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001652935
No open-market purchases or sales by Actuate Therapeutics, Inc. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q2 2026, worth $20.6M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Actuate Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 10 | 19 | +9 |
| Shares | 382.2K | 10.1M | +9.73M (+2,547.0%) |
| Value | $2.85M | $80.5M | +$77.7M (+2,728.2%) |
New holders (13)
Institutions that held Actuate Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BIOS Capital Management, LP | 9,893,651 | $78.8M | 83.69% |
| Voss Capital, LLC | 55,246 | $439.8K | 0.03% |
| Mercer Global Advisors Inc | 16,344 | $130.1K | 0.00% |
| Sigma Planning Corp | 16,075 | $128.0K | 0.00% |
| Vanguard Group Inc | 14,296 | $113.8K | 0.00% |
| Goldman Sachs Group Inc | 11,253 | $89.6K | 0.00% |
| Omers Administration Corp | 10,583 | $84.2K | 0.00% |
| Envestnet Asset Management Inc | 10,465 | $83.3K | 0.00% |
| Freestone Capital Holdings, LLC | 10,000 | $79.6K | 0.00% |
| BlackRock, Inc. | 7,745 | $61.7K | 0.00% |
| UBS Group AG | 1,934 | $15.4K | 0.00% |
| Morgan Stanley | 542 | $4.31K | 0.00% |
| JPMorgan Chase & Co | 3 | $24 | 0.00% |
Sold out (4)
Institutions that held Actuate Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| AWM Investment Company, Inc. | 139,511 | $1.04M |
| Long Corridor Asset Management Ltd | 125,000 | $931.3K |
| Wells Fargo & Company | 3,392 | $25.3K |
| Tower Research Capital LLC (TRC) | 297 | $2.21K |